- Zacks•1 hour ago
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
- Barrons.com•1 hour ago
Credit Suisse One of the most common topics of discussion in our investor meetings remains the question around whether Pfizer or another biopharma company may be interested in acquiring Bristol-Myers Squibb in the next nine-12 months, given some of the challenges Bristol-Myers is facing and the activist involvement in the name. To supplement our previous work, our HOLT [proprietary Credit Suisse platform] colleagues have now taken a look at the possibility of Pfizer buying Bristol-Myers from a HOLT perspective and do see the deal as providing an opportunity for value-creation.
- Motley Fool•20 hours ago
These are the best oncology-focused stocks you can buy this year. Find out which is best suited to boost your portfolio's performance.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.97 - 34.24|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.07|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|